Pharvaris presents deucrictibant trial data

• Pharvaris (NASDAQ:PHVS) presented clinical and translational data on oral bradykinin B2 receptor antagonist deucrictibant at the Bradykinin Symposium 2026.
• Phase 3 RAPIDe-3 data showed faster symptom relief and reduced attack severity compared with placebo.
• Phase 2 CHAPTER-1 extension data showed lower monthly attack rates and continued safety results for long-term prophylactic use.

Pharvaris (NASDAQ:PHVS) presented translational, nonclinical, and clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the Bradykinin Symposium 2026 in Berlin.

The company reported data from laboratory models, including in silico analysis, proteomic studies, and non-human primate models, which evaluated receptor binding, pharmacokinetic relationships, and dose selection for human studies.

Pharvaris reported Phase 3 RAPIDe-3 trial results showing that oral deucrictibant immediate-release capsules shortened median time to symptom relief, reduced attack severity, and improved complete resolution outcomes compared with placebo.

The company reported that End of Progression occurred earlier with deucrictibant than placebo, at 17.5 minutes compared with 228.7 minutes, while Phase 2 CHAPTER-1 extension results showed average attack rates declined from 2.18 to 0.12 attacks per month.

Pharvaris reported that integrated analyses showed a cardiovascular safety profile with stable heart rate, blood pressure, and no QT prolongation or serious arrhythmias observed in the analyzed data.

The company is developing oral therapies for bradykinin-mediated conditions, including hereditary angioedema, using small-molecule approaches designed to target disease pathways.